311 related articles for article (PubMed ID: 29397528)
21. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.
Atallah-Yunes SA; Robertson MJ; Davé UP
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):659-665. PubMed ID: 35577752
[TBL] [Abstract][Full Text] [Related]
23. Emerging therapies in relapsed and refractory peripheral T-cell lymphoma.
Bachow SH; O'Connor OA
Clin Adv Hematol Oncol; 2015 Dec; 13(12):837-46. PubMed ID: 27058850
[TBL] [Abstract][Full Text] [Related]
24. Current Treatment of Peripheral T-cell Lymphoma.
Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray.
Lunning MA
Oncology (Williston Park); 2015 Aug; 29(8):545-50. PubMed ID: 26281838
[TBL] [Abstract][Full Text] [Related]
26. Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
Ong SY; Zain JM
Am J Hematol; 2024 Mar; 99(3):439-456. PubMed ID: 38304959
[TBL] [Abstract][Full Text] [Related]
27. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
Makita S; Maeshima AM; Maruyama D; Izutsu K; Tobinai K
Onco Targets Ther; 2018; 11():2287-2293. PubMed ID: 29719411
[TBL] [Abstract][Full Text] [Related]
28. Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies.
Ng SY; Jacobsen ED
Hematol Oncol Clin North Am; 2019 Aug; 33(4):657-668. PubMed ID: 31229161
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
30. Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.
Epstein-Peterson ZD; Horwitz SM
Semin Hematol; 2021 Apr; 58(2):78-84. PubMed ID: 33906725
[TBL] [Abstract][Full Text] [Related]
31. Peripheral T-cell lymphoma, not otherwise specified.
Broccoli A; Zinzani PL
Blood; 2017 Mar; 129(9):1103-1112. PubMed ID: 28115372
[TBL] [Abstract][Full Text] [Related]
32. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice.
O'Connor OA; Bhagat G; Ganapathi K; Pedersen MB; D'Amore F; Radeski D; Bates SE
Clin Cancer Res; 2014 Oct; 20(20):5240-54. PubMed ID: 25320373
[TBL] [Abstract][Full Text] [Related]
33. Novel therapies for peripheral T-cell lymphomas.
Shustov A
Ther Adv Hematol; 2013 Jun; 4(3):173-87. PubMed ID: 23730495
[TBL] [Abstract][Full Text] [Related]
34. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
Beaven AW; Diehl LF
Hematology Am Soc Hematol Educ Program; 2015; 2015():550-8. PubMed ID: 26637771
[TBL] [Abstract][Full Text] [Related]
35. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
36. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Barbarotta L; Hurley K
J Adv Pract Oncol; 2015; 6(1):22-36. PubMed ID: 26413372
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapeutic advancements in peripheral T-cell lymphoma.
Reddy NM; Evens AM
Semin Hematol; 2014 Jan; 51(1):17-24. PubMed ID: 24468312
[TBL] [Abstract][Full Text] [Related]
38. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
[TBL] [Abstract][Full Text] [Related]
39. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
40. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.
Huang YH; Qiu YR; Zhang QL; Cai MC; Yu H; Zhang JM; Jiang L; Ji MM; Xu PP; Wang L; Cheng S; Zhao WL
Cell Rep Med; 2024 Feb; 5(2):101416. PubMed ID: 38350451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]